Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor ungefähr 5 Jahren |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | vor ungefähr 6 Jahren |
| Titel | Datum |
|---|---|
| MPA Singapore and MISC to support digital transformation in maritime industry | vor ungefähr 5 Monaten |
| The Maritime and Port Authority of Singapore and MISC forge partnership | vor ungefähr 5 Monaten |
| MPA and MISC Partner Up for Maritime Ops Digitalization | vor ungefähr 5 Monaten |
| Malaysia's Gentari, MISC forge strategic partnership to advance ammonia shipping and floating solutions | vor ungefähr 5 Monaten |
| MISC and Gentari forge strategic partnership to advance ammonia shipping and floating solutions | vor ungefähr 5 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |